Skip to content

Efficacy and safety of different doses of aspirin in the prevention of preeclampsia

Efficacy and safety of different doses of aspirin in the prevention of preeclampsia

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800017524
Enrollment
Unknown
Registered
2018-08-02
Start date
2016-01-01
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

preeclampsia

Interventions

1:No oral aspirin
2:Oral aspirin 25mg
3:Oral aspirin 50mg
4:Oral aspirin 75mg

Sponsors

International Peace Maternity & Child Health Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 44 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for high risk population in preeclampsia According to the epidemiological survey, the high risk factors of preeclampsia were: pregnant women over 40 years of age; preeclampsia history; antiphospholipid antibody test results positive; chronic nephritis, primary hypertension or diabetes; body mass index, BMI) in preeclampsia; family history of preeclampsia (mother's family history) This is a multiple pregnancy. The first pregnancy or interval between pregnancies is more than 10 years, the systolic blood pressure in early pregnancy is more than 130mmHg or the diastolic blood pressure is more than 80 mmHg.

Exclusion criteria

Exclusion criteria: The following conditions should be excluded in high-risk groups: chronic history (excluding hypertension, kidney disease, chronic diabetes without hypertension and kidney disease); multiple pregnancies; childbirth in other hospitals; severe fetal malformation; anticoagulant therapy during pregnancy; he has participated in his study on preeclampsia. The following cases disable Aspirin Enteric-coated Tablets: allergy to aspirin or other salicylate, or any other component of the drug; the history of salicylate or salicylic acid or NSAIDs; active peptic ulcers; hemorrhagic physique; severe renal failure; severe liver failure; severe liver failure; severe liver failure; severe liver failure; severe liver failure; severe liver failure; Severe heart failure; combined with methotrexate (dose 15mg/ weeks or more).

Design outcomes

Primary

MeasureTime frame
Uterine artery resistance;Coagulation index;Incidence of preeclampsia;

Countries

China

Contacts

Public ContactGu Wei

International Peace Maternity & Child Health Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University, Shanghai

krisgu70@163.com+86 18017316011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026